Disease block
G40-G47 – Episodische und paroxysmale Krankheiten des Nervensystems
- Chapter VI: Krankheiten des Nervensystems
27Decisions
35Patient groups
Added benefit by patient group
- Considerable6
- Non-quantifiable3
- Not proven26
Diseases in this disease block
- G40 Epilepsie 12 decisions
- G43 Migräne 9 decisions
- G47 Schlafstörungen 6 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2025-11-20VyduraRimegepantNot proven
- 2025-11-20VyduraRimegepantNot proven: 2 of 2 patient groups
- 2025-08-21AquiptaAtogepantNot proven: 2 of 2 patient groups
- 2024-05-16EpidyolexCannabidiolNot proven
- 2024-05-16EpidyolexCannabidiolNot proven
- 2023-10-05RayvowLasmiditanNot proven
- 2023-09-21WakixPitolisantNon-quantifiable
- 2023-08-03FinteplaFenfluraminConsiderable
- 2023-02-16VyeptiEptinezumabNot proven: 2 of 2 patient groups
- 2022-09-01Briviact (in Italy: Nubriveo)BrivaracetamNot proven
- 2022-04-21OzawadePitolisantNot proven
- 2022-03-18SunosiSolriamfetolNot proven
- 2021-11-19OntozryCenobamatNot proven
- 2021-10-21AimovigErenumabConsiderable
- 2021-07-15FinteplaFenfluraminConsiderable
- 2021-06-03FycompaPerampanelNot proven
- 2021-06-03FycompaPerampanelNot proven
- 2020-11-05SunosiSolriamfetolNot proven: 2 of 2 patient groups
- 2019-11-07AjovyFremanezumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-09-19EmgalityGalcanezumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-05-02AimovigErenumabConsiderable
- 2019-01-17Briviact (in Italy: Nubriveo)BrivaracetamNot proven
- 2018-05-17FycompaPerampanelNot proven
- 2017-01-19WakixPitolisantNon-quantifiable
- 2017-01-19HetliozTasimelteonNon-quantifiable
- 2016-08-04Briviact (in Italy: Nubriveo)BrivaracetamNot proven
- 2014-11-06FycompaPerampanelNot proven
Data status: 2026-10-29